We are live on ! Find out more

AN2 Therapeutics

ANTX

Market cap $171M

4.53 USD

-0.16

3.41%

At close Updated Oct 30, 4:00 PM EDT

1 day

-3.41%

5 days

27.61%

1 month

-14.85%

3 months

-15.01%

6 months

-0.44%

Year to date

308.11%

1 year

265.32%

5 years

-70.58%

10 years

-70.58%

About: AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Employees: 21

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 90%

Negative 10%

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.On October 19, 2026, the Compensation Committee granted inducement equity awards to two newly hired employees consisting in the aggregate of options to purchase 10,565 shares of the Company's common stock and 5,2.

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30.

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

AN2 Therapeutics to Participate at Upcoming Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced company management will participate in three upcoming investor conferences in November. Details of the events are as follows: Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026 Eric Easom, Co-Founder, Chairman, President and CEO, will.

AN2 Therapeutics to Participate at Upcoming Investor Conferences

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders. The investigation seeks to determine whether AN2 Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS).

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver

I rate AN2 Therapeutics a speculative buy, with a risk-adjusted base-case valuation of approximately $12 per share versus its September 18 closing price of $5.05. Epetraborole failed in treatment-refractory MAC lung disease, but its dose-dependent and reversible reductions in red-cell parameters could become therapeutic in polycythemia vera. Human and nonhuman-primate data support the erythroid effect, but EBO-PV-201 must demonstrate hematocrit control and reduced phlebotomy without causing clinically important anemia.

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company's newly-appointed Chief Medical Officer.The inducement awards consist of a non-qualified stock option to purchase 233,333 shares of the Company's common stock and restricted stock units representing 116,6.

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onc.

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, onc.

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2026. “AN2 will have three Phase 2 programs underway by the end of this year, all of which have the potential to address major unmet needs. Our near-term focus is advancing start-up activi.

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

See News Rankings

Price charts implemented using Lightweight Charts™